Holen Sie sich die Stockscreener-App
0.45
1.10%
-0.005
Handel nachbörslich:
.43
-0.02
-4.44%
Schlusskurs vom Vortag:
$0.455
Offen:
$0.4677
24-Stunden-Volumen:
357.23K
Relative Volume:
0.47
Marktkapitalisierung:
$15.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.73M
KGV:
-0.217
EPS:
-2.0742
Netto-Cashflow:
$-16.94M
1W Leistung:
-4.90%
1M Leistung:
-16.28%
6M Leistung:
-46.85%
1J Leistung:
-38.02%
1-Tages-Spanne:
$0.45
$0.4948
1-Wochen-Bereich:
$0.44
$0.50
52-Wochen-Spanne:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.45 | 15.20M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView
KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network
Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot - Stock Titan
New Strong Buy Stocks for July 20th - Yahoo Finance
Kartik Krishnan Net Worth (2026) - GuruFocus
Pasithea Therapeutics to present at B. Riley Mi... - Pluang
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire
KTTA Q1 2026 Earnings: Shares Surge on Better-Than-Expected Loss and Operational ProgressRevenue Growth Outlook - dars.gov.et
Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock SurgeTax Rate Impact - dars.gov.et
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView
KTTA Forecast — Price Target — Prediction for 2027 - TradingView
Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView
Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa
Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan
Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks
Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK
Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia
Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria
Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan
Pasithea Therapeutics Corp (KTTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):